FIELD: medicine.
SUBSTANCE: it has been suggested to apply a preparation out of active substance of enamel matrix chosen out of proteins being enamelins, amelogenins, nonamelogenins, proline-enriched nonamelogenins, taftelins and their mixtures for producing pharmaceutical composition for preventing or treating systemic inflammation and/or infection and a corresponding method, as well. The composition in question protects against severe septic shock and polyorganic failure caused by a toxin or severe systemic infection, and decreased levels of TNF and IL-6 illustrate total remission.
EFFECT: higher efficiency.
52 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR MODULATION OF CELL ADHESION MOLECULE EXPRESSION | 2007 |
|
RU2503463C2 |
| USING LYSOZYME DIMER AS DRUG AND COMPOSITIONS CONTAINING THEREOF | 1993 |
|
RU2145875C1 |
| MATRIX PROTEIN COMPOSITIONS FOR HEALING WOUND | 1999 |
|
RU2241489C2 |
| LINEAR OR CYCLIC PEPTIDES, THEIR USING AND METHOD OF PATIENT TREATMENT | 1993 |
|
RU2130317C1 |
| CHAPERONIN 10 MODULATION OF TOLL-LIKE RECEPTOR INDUCIBLE CYTOKINE AND CHEMOKINE SECRETION | 2005 |
|
RU2446817C2 |
| 5-(4-METHANESULPHONYL PHENYL)THIAZOLE DERIVATIVES FOR TREATING ACUTE AND CHRONIC INFLAMMATORY DISEASES | 2009 |
|
RU2495031C2 |
| BIOLOGICAL MATERIALS AND THEIR USE | 2009 |
|
RU2508296C2 |
| USE OF ARSENIC COMPOUNDS TO TREAT TISSUE OR ORGAN REJECTION | 2013 |
|
RU2665362C2 |
| AGONISTS OF NICOTINE RECEPTORS IN TREATMENT OF INFLAMMATORY DISEASES | 2002 |
|
RU2299731C2 |
| IMPROVED IMMUNOLOGICAL COMPOSITION | 2012 |
|
RU2664730C2 |
